A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma.
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Daratumumab (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 18 Sep 2017 Status changed from not yet recruiting to recruiting.
- 08 Feb 2017 New trial record